Does Thyroxine Cause Elevated SHBG?
Yes, levothyroxine (thyroxine) increases sex hormone-binding globulin (SHBG) levels in a dose-dependent manner. This is a well-established effect documented in both FDA labeling and clinical research.
Mechanism and Evidence
The FDA drug label explicitly states that levothyroxine increases serum thyroxine-binding globulin (TBG) concentration, though it notes this occurs "without affecting free thyroxine (FT4) concentration" in the context of maintaining euthyroidism 111. However, the relationship with SHBG specifically is more nuanced.
Clinical research consistently demonstrates that thyroid hormone status directly affects SHBG levels:
- SHBG levels are increased in hyperthyroid states and decreased in hypothyroid states 2
- This relationship is positively correlated with free thyroid hormone concentrations in both men and women 2
- When hypothyroid patients receive levothyroxine treatment, SHBG concentrations increase significantly (p < 0.01) as they achieve euthyroid status 2
Dose-Dependent Response
The effect is dose-dependent and occurs with both therapeutic and supraphysiologic doses:
- In normal subjects, SHBG increases in a dose-dependent manner with both L-T4 and L-T3 therapy, correlating positively with serum thyroid hormone levels 3
- Even in hypothyroid patients with normalized TSH on standard levothyroxine therapy, the SHBG elevation persists 3
- The increase precedes testosterone elevation in males 3
Clinical Significance
In comparative studies, LT3 (liothyronine) produces greater SHBG elevation than LT4 (levothyroxine):
A 2022 randomized crossover trial in symptomatic hypothyroid women found that SHBG increased significantly more with LT3 treatment compared to LT4 treatment, despite both maintaining TSH within reference range 4. This suggests that the more metabolically active T3 has a stronger effect on hepatic SHBG production.
Important Caveats
The SHBG elevation from levothyroxine is a marker of adequate thyroid hormone action at the liver level, not an adverse effect per se 2. However, clinicians should be aware:
- In patients on suppressive doses of levothyroxine (for thyroid cancer or nodular goiter), one older study found no significant difference in SHBG values between treated patients and controls when carefully matched for menopausal status and BMI 5, though this conflicts with other data
- The clinical impact depends on the patient's sex hormone status and whether changes in free (bioavailable) sex hormones occur
- While SHBG rises, the percentage of free testosterone may decrease, though the absolute mass of free testosterone often remains unchanged 6
Bottom Line for Practice
When you see elevated SHBG in a patient on levothyroxine therapy, this is an expected physiologic response indicating adequate thyroid hormone effect at the hepatic level. It should not prompt dose reduction unless there are other signs of overtreatment (suppressed TSH, hyperthyroid symptoms, cardiovascular effects, or bone loss concerns) 7. The SHBG elevation itself confirms that thyroid hormone is reaching target tissues and exerting metabolic effects.